Physician profile
Deborah J Dunham
NPI 1518079037
$7,806.25
in general payments reported to CMS, 2019-2025
28 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,092 · 2022: $1,449 · 2023: $1,496 · 2024: $2,087 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,265.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,265.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,194.16 | 2021-2025 | Biomonitor, Amvia Edge, Renamic Neo |
| Cvrx, INC. | $954.14 | 2021-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $947.54 | 2021-2025 | Verquvo, Capvaxive, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $831.54 | 2021-2025 | |
| Abbott Laboratories | $499.78 | 2023-2025 | Mitraclip, Aveir, Jot Dx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $408.87 | 2021-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $377.04 | 2023-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $346.80 | 2021-2025 | Farapulse |
| Amgen INC. | $328.18 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $259.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $255.10 | 2021-2025 | Farxiga |
| Scpharmaceuticals INC. | $196.89 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $189.14 | 2024 | Inpefa |
| Janssen Pharmaceuticals, INC | $162.55 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $145.07 | 2021-2025 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $124.99 | 2023 | Mounjaro |
| Alnylam Pharmaceuticals INC. | $119.32 | 2022-2024 | Amvuttra, Onpattro |
| Pfizer INC. | $81.34 | 2021-2024 | |
| Impulse Dynamics (USA) INC. | $80.36 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals International, Plc | $76.82 | 2024 | Arcalyst |
| Abiomed | $40.14 | 2025 | |
| Amarin Pharma, INC. | $38.04 | 2021 | |
| Esperion Therapeutics, INC. | $35.11 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $29.11 | 2024 | Evkeeza |
| Kestra Medical Technology Services, INC. | $28.55 | 2025 | Assure Wcd |
| Philips North America LLC | $22.67 | 2023 | |
| Glaxosmithkline, LLC. | $21.54 | 2022 | |
| G Medical Diagnostic Services, INC. | $12.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Dunham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.